Hoping to repeat its Phase II success, privately held NovaRx Corp. launched a pivotal study of therapeutic vaccine Lucanix (belagenpumatucel-L) in non-small-cell lung cancer (NSCLC) patients under a special protocol assessment approved early this year. (BioWorld Today) Read More
No AbstractSpePharm Holding BV closed on a €16 million (US$23.8 million) equity financing round to fund ongoing growth and entered into a €10 million revenue interest acquisition financing agreement related to its purchase of Dantrium for Europe and other markets from Procter & Gamble Pharmaceuticals, a division of P&G, of Cincinnati.The special pharma company and JHP Pharmaceuticals LLC recently closed on their purchase of Dantrium (Dantrolene Sodium). Read More
